Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 44

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 44
---
expense):    Interest income8,534 5,482 20,437 14,134 Interest expense(4,279)(4,689)(13,554)(11,889)(Loss) gain on early extinguishment of debt(983)— (983)7,518 Other, net(110)(122)(6,448)(320)          Total other income (expense), net3,162 671 (548)9,443 Income (loss) before income taxes9,524 (138,856)16,303 (88,632)Income tax expense(4,092)(4,610)(10,906)(26,969)Net income (loss)$5,432 $(143,466)$5,397 $(115,601)Net income (loss) per common share:    Basic and diluted net income (loss) per common share$0.12 $(3.11)$0.12 $(2.50)Weighted average common shares outstanding:       Basic44,038 46,134 45,257 46,269      Diluted44,459 46,134 45,729 46,269     

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  3

Table of Contents

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30, 2025202420252024Net income (loss)$5,432 $(143,466)$5,397 $(115,601)Other comprehensive income (loss):  Net unrealized gain (loss) on investments, net of tax29 597 (102)437 Foreign currency translation adjustments32 (24)3,882 (6)Total other comprehensive income61 573 3,780 431 Comprehensive income (loss)$5,493 $(142,893)$9,177 $(115,170)

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  4

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLID